BioCentury
ARTICLE | Product R&D

Branching out

Symic's proteoglycan mimetics branch out

April 7, 2016 7:00 AM UTC

With its second compound about to hit the clinic and a fresh influx of money, Symic Biomedical Inc. is lining up the next three preclinical programs for its extracellular matrix (ECM)-targeting technology. By applying each of its first five programs to a different therapeutic area, the company hopes to showcase the broad flexibility of its platform, and is creating a corporate structure to enable it to build up or spin out any area as the opportunity arises.

The first two programs were in cardiovascular disease and osteoarthritis. Now Symic has added fibrosis, oncology and CNS disorders. ...